Compare iShares Global Clean Energy ETF (ICLN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Merck & Co., Inc. — how do they compare? iShares Global Clean Energy ETF trades at $17.22 (market cap $2.27B), while Merck & Co., Inc. trades at $144.83 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 154.7× iShares Global Clean Energy ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares Global Clean Energy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and Merck & Co., Inc. for 98 Days on average.
| ICLN | MRK | |
|---|---|---|
Market Cap | $2.27B | $351.28B |
Volume | 6,845,064 | 7,969,665 |
52-Week High | $23.75 | $156.43 |
52-Week Low | $15.78 | $82.49 |
Typical Hold Time | 87 Days | 98 Days |
Sector | — | Health |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.17, down 0.81% with bearish technical signals from moving averages. The ETF shows neutral momentum oscillators but faces significant volatility compared to traditional energy peers. Recent news highlights ICLN's 57.2% maximum drawdown and higher expense ratio of 0.38% versus fossil fuel ETFs, though geopolitical tensions are driving renewed interest in renewable energy infrastructure.
The clean energy sector faces competitive pressure from higher-yielding traditional energy ETFs, but long-term growth prospects remain supported by global energy transition trends. Key risks include expense ratio disadvantages and sector volatility, while potential catalysts include increased renewable adoption driven by geopolitical and environmental factors.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
